iniparib   Click here for help

GtoPdb Ligand ID: 8360

Synonyms: BSI-201 | SAR240550
PDB Ligand
Compound class: Synthetic organic
Comment: Iniparib was reported as PARP1 inhibitor [2] (or rather its metabolite 4-iodo-3-nitrosobenzamide was reported to inhibit PARP1 activity), however this action has been disputed [1,4].

iniparib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 86.23
Molecular weight 291.93
XLogP 1.87
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES [O-][N+](=O)c1cc(ccc1I)C(=O)N
Isomeric SMILES [O-][N+](=O)c1cc(ccc1I)C(=O)N
InChI InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
InChI Key MDOJTZQKHMAPBK-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Iniparib reached Phase 3 clinical trial. Clinical trials used iniparib as a co-therapy with other antineoplastics such as gemcitabine/carboplatin, doxorubicin, paclitaxel and topotecan. Indications investigated in trials include triple negative metastatic breast cancer [3], squamous non-small-cell lung cancer (NSCLC) and other solid tumours. Click here to link to ClinicalTrials.gov's full list of Phase 3 iniparib trials. Due to insufficient evidence of clinical benefit the manufacturer (Sanofi) has discontinued development of iniparib.